S. 652 would amend the Public Health Service Act to reauthorize research and public health activities conducted by the Health Resources and Services Administration (HRSA) and the Centers for Disease Control and Prevention (CDC). Those activities are related to early detection, diagnosis, and treatment of hearing loss in newborns, infants, and young children.
CBO estimates that implementing S. 652 would cost $127 million over the 2017-2022 period, assuming appropriation of the specified amounts.
Pay-as-you-go procedures do not apply to this legislation because it would not affect direct spending or revenues.
CBO estimates that enacting S. 652 would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2028.
S. 652 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.
